2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Arthritis, Rheumatoid
19
Spondylitis, Ankylosing
6
Psoriasis
4
Colitis, Ulcerative
4
Crohn Disease
3
Inflammatory Bowel Diseases
2
Uveal Melanoma
1
Thyroid Carcinoma, Anaplastic
1
Spondylarthritis
1
Sarcoidosis
1
Recurrence
1
Plaque Psoriasis
1
Osteoarthritis
1
Nephrotic Syndrome
1
Nephrosis, Lipoid
1
Mucopolysaccharidosis VI
1
Mucopolysaccharidosis II
1
Mucopolysaccharidosis I
1
Mucopolysaccharidoses
1
Melanoma
1
Macular dystrophy, corneal type 1
1
Kidney Diseases
1
Joint Diseases
1
Inflammation
1
Infections
1
Hidradenitis Suppurativa
1
Healthy Adult Male
1
Healthy
1
Glomerulosclerosis, Focal Segmental
1
Dupuytren Contracture
1
Interventions
Metformin
2
Saline Solution
1
Lidocaine
1
Injections, Intradermal
1
Gels
1
Cyproterone Acetate
1
Cetuximab
1
Adrenal Cortex Hormones
1
Adalimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Acne Vulgaris
×
Adalimumab
×
Clear all
NCT01635764
2018-01-24
PIONEER (OLE)
AbbVie
Phase 3
Completed
508 enrolled
9 charts